MAPT and Alzheimer disease: And in a phase 3 clinical trial of the anti-Aß antibody bapaineuzumab for mild-to-moderate AD, reductions of both Aß and tau levels were observed in APOE4+ AD patients, but not in APOE4− AD patients [130].